Share Twitter LinkedIn Facebook Email Dr. John Kisiel, MD, Mayo Clinic, talks Setting Specificity and Sensitivity for Tests | Involves recruiting up to 500 At-Risk Control Patients for DDW 2018
SGNTUC-024 Phase 1b/2 study: Tucatinib, trastuzumab, FOLFOX for HER2+ GI cancers Gastrointestinal 8 Mins Read